Issue Areas

Drug Pricing

Bringing High-Value Therapies to Patients

INTRO STATEMENT
Learn more

Kaiser Permanente believes it is time for a new legal and policy landscape for drug pricing that rewards innovation and discovery, but also provides medicines at prices patients and the health care system can afford.

Featured content Events Our experts

Featured content

Drug Policy 101 Series

Drug policy 101: Kaiser Permanente’s Approach to Pharmaceutical Detailing
pile of 20 dollar bills and medicine containers on white background
How pharmaceutical marketing affects decisions about patient care
pharma marketing 101
Drug policy 101: Pharmaceutical marketing tactics
Drug policy 101: Breaking down different types of drug products
Drug policy 101: The state of the pharmaceutical evidence base
Drug policy 101: Drug patents
Drug policy 101: Biosimilars
Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)
Drug Policy 101: Pay-for-delay

Drug pricing presenters

Click a speaker to view their full bio.

Barbara DiPietro
Barbara DiPietro, MD
Senior Director of Policy, National Health Care for the Homeless Council
Margot Bushel
Margot Kushel, MD
Director of the UCSF Benioff Homelessness and Housing Initiative
Rishi Miranda
Rishi Manchanda, MD
President & CEO, HealthBegins
Cecilia Echeverría
Cecilia Oregón, MPP, MPH
Executive Director, Kaiser Permanente Institute for Health Policy
Jacqueline Waggoner
Jacqueline Waggoner
President, Solutions Division, Enterprise Community Partners, Inc.